Cargando…

FIGNL1 is overexpressed in small cell lung cancer patients and enhances NCI-H446 cell resistance to cisplatin and etoposide

Abnormal DNA repair plays an important role in tumor occurrence, progression and resistance to therapy. Fidgetin-like 1 (FIGNL1) expression was assayed in 42 small cell lung cancer (SCLC) and 45 normal lung specimens from Chinese patients by qRT-PCR. Notably, FIGNL1 was upregulated by 1.5-fold in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Jian, Li, Jianlei, Yao, Xiaoling, Lin, Shuangjun, Gu, Ye, Xu, Jianfang, Deng, Zixin, Ma, Wei, Zhang, Haiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367342/ https://www.ncbi.nlm.nih.gov/pubmed/28260065 http://dx.doi.org/10.3892/or.2017.5483

Ejemplares similares

Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells
por: Zhang, Z, et al.
Publicado: (2013)

The effects of HIF-1alpha on gene expression profiles of NCI-H446 human small cell lung cancer cells
por: Wan, Jun, et al.
Publicado: (2009)

FIGNL1 promotes non-small cell lung cancer cell proliferation
por: Li, Miao, et al.
Publicado: (2020)

Wnt inhibitor XAV939 suppresses the viability of small cell lung cancer NCI-H446 cells and induces apoptosis
por: Guo, Wenxuan, et al.
Publicado: (2017)

Metformin synergistically enhances antiproliferative effects of cisplatin and etoposide in NCI-H460 human lung cancer cells
por: Teixeira, Sarah Fernandes, et al.
Publicado: (2013)

Down-regulation of GRP78 is associated with the sensitivity of chemotherapy to VP-16 in small cell lung cancer NCI-H446 cells
por: Wang, Yingyan, et al.
Publicado: (2008)

Effects of three IL-15 variants on NCI-H446 cell proliferation and expression of cell cycle regulatory molecules
por: Ding, Jun-Ying, et al.
Publicado: (2017)

Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells
por: Wang, Guoquan, et al.
Publicado: (2016)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

The Rice AAA-ATPase OsFIGNL1 Is Essential for Male Meiosis
por: Zhang, Peipei, et al.
Publicado: (2017)

FIGNL1 Inhibits Non-homologous Chromosome Association and Crossover Formation
por: Yang, Shuying, et al.
Publicado: (2022)

Inactivated Tianjin strain, a novel genotype of Sendai virus, induces apoptosis in HeLa, NCI-H446 and Hep3B cells
por: CHEN, JUN, et al.
Publicado: (2016)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
por: Berghmans, Thierry, et al.
Publicado: (2017)

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines
por: Busch, Maike, et al.
Publicado: (2018)

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines
por: Kondo, Hideki, et al.
Publicado: (1994)

miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2
por: Liu, Hui-Ning, et al.
Publicado: (2018)

Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer
por: Xiao, Xiaoguang, et al.
Publicado: (2015)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro
por: XU, XIAO-MAN, et al.
Publicado: (2013)

Microtubule Severing Protein Fignl2 Contributes to Endothelial and Neuronal Branching in Zebrafish Development
por: Dong, Zhangji, et al.
Publicado: (2021)

FIRRM cooperates with FIGNL1 to promote RAD51 disassembly during DNA repair
por: Pinedo-Carpio, Edgar, et al.
Publicado: (2023)

人小细胞肺癌NCI-H446裸鼠模型的(99m)Tc-octreotide受体显像研究
Publicado: (2015)

Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
por: Xie, Zhanhong, et al.
Publicado: (2019)

Synergistic anti-proliferative and pro-apoptotic activities of 5F and cisplatin in human non-small cell lung cancer NCI-H23 cells
por: Li, Yuchan, et al.
Publicado: (2017)

Combination Chemotherapy with Cyclophosphamide, Vincristine, Cisplatin and Etoposide(COPE) Combined with Radiotherapy for Small Cell Lung Cancer
por: Nam, Yong Jin, et al.
Publicado: (1995)

Pharmacoeconomic benefit of cisplatin and etoposide chemoregimen for metastatic non small cell lung cancer: An Indian study
por: Kamath, Mangesh P, et al.
Publicado: (2016)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
por: Sun, Yan, et al.
Publicado: (2016)

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
por: Zangemeister-Wittke, U., et al.
Publicado: (1998)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report
por: Das, Sunil Kumar, et al.
Publicado: (2022)

Recombinant immunotoxin targeting GPC3 is cytotoxic to H446 small cell lung cancer cells
por: Rodakowska, Ewelina, et al.
Publicado: (2021)

Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer
por: Goto, K, et al.
Publicado: (2004)

Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients
por: Faivre, C, et al.
Publicado: (2017)

阿帕替尼联合CCI-779体外抑制小细胞肺癌细胞株NCI-H446的增殖和迁移
Publicado: (2020)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Sen, Fatma, et al.
Publicado: (2016)

A case of small-cell esophageal cancer with chronic renal failure undergoing hemodialysis safely treated with cisplatin and etoposide
por: Murakami, Kentaro, et al.
Publicado: (2011)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
por: Jiang, Shiyu, et al.
Publicado: (2021)

Localized Colonic Small-Cell Carcinoma with Pathological Complete Response after Neoadjuvant Cisplatin and Etoposide: A Case Report
por: Alía Navarro, Víctor, et al.
Publicado: (2023)

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer
por: Kim, Dong-Wan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rhoedd2mmnpgn2mrmgas635nfg